Caricamento quotazioni...

Previsioni

Il prezzo obiettivo medio degli analisti è 28,62 € (+8,61%). La mediana è 27,71 € (+5,16%).

Acquista
  16
Mantieni
  23
Vendi
  1

Discussioni nella community

  • Tradotto (originale in tedesco)

    🔝Aggiornamento: Strada verso la Luna 🚀 — il mio portafoglio, il mio percorso

    Bakterius Bakterius II in Portfolio Roasts

    9 19
  • Tradotto (originale in tedesco)

    Roast my Portfolio – Il mio percorso verso la libertà finanziaria 📈

    Nekromannte Nekromannte IV in Portfolio Roasts

    9 28
  • Tradotto (originale in tedesco)

    Dividendi regolari

    Bakterius Bakterius II in Schnack

    1 61
  • Tradotto (originale in tedesco)

    HIMS & HERS HEALTH FUTURO

    Struemp Struemp I in Schnack

    0 6
  • Tradotto (originale in tedesco)

    I consumi di base stanno salendo

    MB Marc B. IV in Schnack

    7 22

  • Pfizer beats Q3 estimates, raises full-year guidance and appoints Cecile Guegan as CFO

    Pfizer reported third-quarter adjusted EPS of $0.87 and revenue of $16.58 billion, both above consensus, and raised its full-year revenue outlook to $62–64 billion. The company also raised full-year adjusted EPS guidance to $2.95–3.05. Cecile Guegan, a long-time finance executive who served as interim CFO since August, has been named chief financial officer. Management cited strong year-to-date performance and ongoing cost cuts as drivers of the outlook improvement. » Altro su cnbc.com


  • Pfizer yields 6.2% with payout supported by free cash flow and cost cuts

    Pfizer’s dividend yields about 6.2%, one of the highest in the S&P 500, and its trailing 12‑month free cash flow of nearly $11 billion exceeds roughly $9.8 billion in cash dividends, supporting payout sustainability. The company is cutting expenses to strengthen finances as it navigates its next growth phase. By contrast, Eli Lilly offers minimal yield (~0.6%) but has delivered rapid dividend growth driven by strong GLP‑1 profits, making Lilly a growth-plus-income option while Pfizer suits yield-focused investors. » Altro su finance.yahoo.com


  • Pfizer and Trump administration agree to revenue-sharing from higher drug prices abroad

    A largely redacted contract shows that Pfizer must hand over part of additional net revenues from higher drug prices abroad to the U.S. Department of Health and Human Services (HHS). The agreement runs from January 1, 2026, to January 20, 2029; the percentage rate, the drugs affected and the allocation of the funds are secret. Pfizer stresses its contribution to relieving U.S. patients, analysts view the deal as politically advantageous for the company, while other markets could be burdened by higher prices. » Altro su deraktionaer.de


  • Pfizer says major headwinds are easing as pipeline and cost cuts aim to offset Eliquis cliff

    CEO Albert Bourla says Pfizer has addressed tariff and pricing pressures and COVID product declines are less impactful, while the company has beaten EPS estimates in recent quarters. Pfizer reports $13 billion in annualized revenue from newer and acquired products and has cut about $7.2 billion in costs to help offset upcoming patent expirations. Major risks remain as Eliquis and Ibrance face U.S. patent cliffs in 2028 and 2027 respectively, but management expects oncology and weight‑loss programs plus other pipeline assets to deliver launches by the end of the decade. Pfizer maintains a high forward dividend yield (6.2%) and is likely to keep payouts intact while revenue may dip in the near term as patent losses are navigated. » Altro su finance.yahoo.com


  • Pfizer Lyme vaccine application enters EMA review despite Phase 3 statistical caveat

    The EMA has validated the marketing application for PF-07307405, the Pfizer–Valneva Lyme vaccine, and begun formal review. The submission is based on the Phase 3 VALOR trial showing >70% efficacy and no safety signals, but the primary prespecified analysis missed its predefined statistical confidence-bound threshold while a second analysis met it. Approval would leave the partners with little direct competition in Europe, but review timelines, pricing and commercialization details remain uncertain and the market reaction was muted. » Altro su finance.yahoo.com

Nel 2026, Pfizer ha già distribuito 1,11 € di dividendi. L'ultimo pagamento è avvenuto a settembre.

Dati finanziari dell'azienda

Nell'ultimo trimestre, Pfizer ha registrato ricavi pari a 14,57 Mld € e un utile netto di 2,85 Mld €
(EUR) settembre 2026
YoY
Ricavi 14,57 Mld 2,45%
Utile lordo 11,03 Mld 3,49%
Utile netto 2,85 Mld 5,80%
EBITDA 4,94 Mld 2,46%

Dati fondamentali

Metrica Valore
Capitalizzazione di mercato
149,62 Mld €
Numero di azioni
5,7 Mld
Massimo/minimo a 52 settimane
28,57 € - 21,46 €
Rendimento da dividendo
5,66%
Dividendi TTM
1,48 €
Prossimo dividendo
0,39 €
Beta
0,30
Rapporto P/E
40,87
Rapporto PEG
-0,69
Rapporto P/B
1,85
Rapporto P/S
2,59

Profilo aziendale

Pfizer Inc. scopre, sviluppa, produce, commercializza, distribuisce e vende prodotti biofarmaceutici in tutto il mondo. Offre farmaci e vaccini in diverse aree terapeutiche, tra cui cardiovascolare, metabolico e salute della donna, con i marchi della famiglia Premarin ed Eliquis; biologici, piccole molecole, immunoterapie e biosimilari con i marchi Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena e Braftovi; e farmaci iniettabili sterili e anti-infettivi, nonché il trattamento orale contro la COVID-19, con i marchi Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga e Paxlovid. L'azienda fornisce inoltre farmaci e vaccini in diverse aree terapeutiche, come malattia pneumococcica, malattia meningococcica, encefalite da zecche e COVID-19, con i marchi Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba e la famiglia Prevnar; biosimilari per malattie croniche immunitarie e infiammatorie con i marchi Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis e Cibinqo; e prodotti per amiloidosi, emofilia e malattie endocrine con i marchi Vyndaqel/Vyndamax, BeneFIX e Genotropin. Inoltre, l'azienda è attiva nel settore della produzione per conto terzi. Serve grossisti, dettaglianti, ospedali, cliniche, agenzie governative, farmacie e studi medici individuali, nonché centri per il controllo e la prevenzione delle malattie. L'azienda ha accordi di collaborazione con Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; e Arvinas, Inc. Pfizer Inc. è stata fondata nel 1849 ed ha sede a New York, New York.

Nome
Pfizer
CEO
Albert Bourla
Sede centrale New York City, ny
Stati Uniti
Sito web
Settore
Sanità
Industria
Prodotti farmaceutici
Quotazione in borsa
26/02/2021
Dipendenti 75.000

Simboli di borsa

Borsa Simbolo
NYSE
PFE
XETRA
PFE.DE
XETRA
PFE.F
Frankfurt
PFE.F
Düsseldorf
PFE.DU
Hamburg
PFE.HM
Milan
1PFE.MI
London
0Q1N.L
SIX
PFE.SW
München
PFE.MU
Wien
PFE.VI
🍪

Parqet  usa i cookie. Scopri di più